Electra Therapeutics, Inc. Common stock (ETRA) FinancialsETRAElectra Therapeutics, Inc. Common stock

In the context of the broader market, ETRA competes directly with industry leaders such as ACRS and DBVT. With a market capitalization of $548.68M, it holds a significant position in the sector. When comparing efficiency, ETRA's gross margin of N/A stands against ACRS's 10.80% and DBVT's 100.00%. Such benchmarking helps identify whether Electra Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Electra Therapeutics has a price-to-book ratio of -21.688, indicating negative equity, and both its PE and forward PE ratios are 0, suggesting no earnings are currently being generated.